Yes, biopharma still has a reputation problem. These leaders are looking for solutions.

Negative news is breaking down the public’s perception of the biopharma industry — but leaders around the industry have some ideas to fix it.

By Michael Gibney • June 8, 2023

Ranking reveals biopharma’s most innovative companies

IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.

By Taren Grom • June 7, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Woman of the Week: Marinus Pharmaceuticals’ Christy Shafer

The chief commercial officer shares how the company “beat the odds” to bring a rare disease drug to market.

By Taren Grom • June 7, 2023

BIO’s CEO digs into the hot-button issues facing the industry

Rachel King took the reins at BIO during a rocky time. Now, after steadying the ship, she’s brought the trade association’s focus back to the industry’s most pressing priorities.

By Alexandra Pecci • June 5, 2023

Janssen and Legend’s longtime collaboration lands a CAR-T win at ASCO

A partnership going on six years between the pharma giant and the Chinese biotech is showing that their CAR-T cell therapy for multiple myeloma is highly effective.

By Michael Gibney • June 5, 2023

Woman of the Week: Mirati Therapeutics’ Laurie Stelzer

With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial organization.

By Taren Grom • May 31, 2023

The ‘superpowers’ pharma leaders should cultivate

Executives honored by the Healthcare Businesswomen’s Association share the key traits that help them drive results.

By Taren Grom • May 26, 2023

From FTC to SCOTUS, Amgen’s woes are potential ‘game changers’ for the industry

The two institutional battles offer a glimpse into the tension between pharma innovation and regulation that could reverberate across the industry.

By Michael Gibney • May 25, 2023

Woman of the Week: Cognition Therapeutics’ Lisa Ricciardi

As CEO of the neurogenerative company, Ricciardi is applying her decades of “human capital” to advance Alzheimer’s and dementia treatments.

By Taren Grom • May 24, 2023

The cell ‘atlasing’ approach pushing the limits of drug discovery

Vizgen’s CEO discusses the potential of spatial genomics in the life sciences and the company’s role in the movement.

By Taren Grom • May 24, 2023

Biotechs blast experiments into space

Conducting life sciences research in space’s microgravity could have far-ranging implications for drug development on Earth.

By Alexandra Pecci • May 23, 2023

Strangers in a strange land: 8 unlikely companies making plays in pharma

How these consumer and service companies are tapping into major trends in the biopharma industry.

By Karissa Waddick • May 22, 2023

Amid surging Duchenne market, Capricor touts potential ‘backbone’ therapy of the space

The company's CEO on the vital role its late-stage candidate could play in the lives of DMD patients. 

By Kelly Bilodeau • May 22, 2023

What pharma can teach biotech about the life cycle management of a drug

Global product teams are common in pharma but have yet to gain traction in biotech. Here's why this model can work.

By Dr. Stephen Dale and Kathleen Ford • May 18, 2023

Woman of the Week: Genentech’s Veronica Sandoval

How the Genentech diversity exec is using ‘three Ms’ to reduce health disparities and improve access for under-supported communities.

By Taren Grom • May 17, 2023

From farm to pharma: How cows could play a role in the next flu breakthrough

SAb Biotherapeutics is working on a novel product that uses cow antibodies genetically engineered into human antibodies to prevent and treat infectious diseases.

By Alexandra Pecci • May 16, 2023

How pharma’s rocky real estate market has changed — for better and worse

Whether you’re looking to build a new site or expand lab space, here are the biggest trends impacting life sciences real estate.

By Karissa Waddick • May 11, 2023

Woman of the Week: Reneo Pharmaceuticals’ Ashley Hall

After ushering a blockbuster to market, the chief development officer is channeling her experience into the rare disease space.

By Taren Grom • May 10, 2023

Led by the Pfizer-Seagen deal, ADCs are starting to ‘take center stage’

Antibody-drug conjugates got a major boost with the megamerger of Pfizer and Seagen, and experts believe they will continue to be an important catalyst in biopharma.

By Michael Gibney • May 9, 2023

This ‘hot-blooded’ CEO is aiming to transform the way burn victims heal

Cutiss CEO Daniela Marino is funneling her bold personality and expertise in regenerative medicine into a startup developing bioengineered skin grafts.

By Alexandra Pecci • May 9, 2023

3 key FDA approval trends this year

Although approvals are off to a slow start in oncology, the agency has been living in the fast lane for neurological disorders and more.

By Kelly Bilodeau • May 8, 2023

How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

By Taren Grom • May 5, 2023

A biopharma CEO opens up about executive salaries — and why he wants to change the status quo

With leaders at the biggest biopharma companies bringing in millions, the CEO of Corvus Pharmaceuticals opted for a pay cut to pour more funds into science.

By Michael Gibney • May 4, 2023

Navigating workforce challenges amid a turbulent biopharma market

A number of biopharma companies slashed their workforces this year and as market anxieties persist, more challenges could be looming.

By Karissa Waddick • May 4, 2023

Woman of the Week: Jazz Pharmaceuticals’ Neena Patil

Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.

By Taren Grom • May 3, 2023